AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1161368
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of systematic preparation, rehearsal, and supportive care conducted prior to each stressful procedure
Trial: 1161368
Drug: Single-session preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-session preparation conducted after admission
Trial: 1161368
Drug: Consistent supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consistent supportive care given by one nurse at the same points as in the first condition, but including no systematic preparation or rehearsal
Trial: 30981618
Drug: Neodymium: yttrium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neodymium: yttrium aluminum garnet laser treatment
Trial: 22097347
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (GBE) (three pills, tid)
Trial: 22097347
Drug: Placebo (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (three pills, tid)
Trial: 22429128
Drug: Slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release doxycycline gel (SRD) administered adjunctively to subgingival ultrasonic/sonic instrumentation (USI)
Trial: 22429128
Drug: Slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release doxycycline gel (SRD)
Trial: 2798445
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day aspirin
Trial: 2798445
Drug: 1000 mg/day
RxNorm normalized name: RibaTab 1000 MG/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/day aspirin
Trial: 11442187
Drug: Brimonidine as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine as adjunctive therapy
Trial: 11442187
Drug: Brimonidine added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine added to nonselective beta-blocker monotherapy
Trial: 11442187
Drug: Brimonidine added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine added to latanoprost monotherapy
Trial: 11442187
Drug: Brimonidine added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine added to combination regimens including latanoprost
Trial: 11442187
Drug: Physician rating
RxNorm normalized name: Aratinga erythrogenys feather extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician rating of brimonidine adjunctive therapy
Trial: 8062504
Drug: 3-hydroxybutyrate infusion
RxNorm normalized name: 2-Amino-3-hydroxybutyric acid
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-hydroxybutyrate infusion
Trial: 10195546
Drug: Propofol 3
RxNorm normalized name: fospropofol 35 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 3 mg/kg
Trial: 15310636
Drug: 4 mL
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL saline (placebo)
Trial: 12213884
Drug: rhIGF‐I (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF‐I (30 μg/kg·d) for 1 yr
Trial: 12213884
Drug: 100 μg/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg/L IGF‐I (13 nM)
Trial: 70585
Drug: ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ursodeoxycholic acid (600 mg/day)
Trial: 70585
Drug: ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ursodeoxycholic acid (150 mg/day)
Trial: 15668544
Drug: EFV 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EFV 600 mg once daily
Trial: 23294034
Drug: AZV/r 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZV/r 300 mg and ritonavir 100 mg once daily
Trial: 23294034
Drug: LPV/r 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPV/r 400 mg and ritonavir 100 mg twice daily
Trial: 21812910
Drug: Subcutaneous infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous infiltration of ketamine 1 mg/kg (Group KS1)
Trial: 21812910
Drug: Subcutaneous infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous infiltration of ketamine 2 mg/kg (Group KS2)
Trial: 21812910
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine 1 mg/kg (Group KI)
Trial: 21812910
Drug: Subcutaneous infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous infiltration of normal saline 20 mL (Group C)
Trial: 18194386
Drug: MBL deficiency
RxNorm normalized name: vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBL deficiency (MBL ≤ 80 ng/mL)
Trial: 16472564
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 - Initial injection on 1st-5th day of menstrual cycle, subsequent injections every 30 +/- 3 days.
Trial: 16472564
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 - Initial injection between Days 7 and 10 of menstrual cycle, subsequent injections 7-10 days after Day 1 of withdrawal bleeding.
Trial: 10473015
Drug: Frequent testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frequent testing (twice per week) for 10 weeks
Trial: 10473015
Drug: Less frequent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less frequent testing (approximately weekly or every 3-4 weeks)
Trial: 25741816
Drug: Ocriplasmin 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocriplasmin 125 μg
Trial: 16493123
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (450 mL daily, 40 grams of alcohol)
Trial: 16493123
Drug: De-alcoholized red
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: De-alcoholized red wine (450 mL daily)
Trial: 27164691
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (1,000 IU orally twice daily for 3 years)
Trial: 16627836
Drug: Nebulisation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulisation with a combination of salbutamol (0.5 mg) and magnesium sulphate (500 mg)
Trial: 16627836
Drug: Nebulisation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulisation with salbutamol only (0.5 mg)
Trial: 11903240
Drug: Emulsifying ointments
RxNorm normalized name: diazepam
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emulsifying ointments (unguentum emulsificans and dilutions with 30, 50, 70 and 90% aqua purificans)
Trial: 9860106
Drug: Flunitrazepam 2
RxNorm normalized name: flunitrazepam 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam 2 mg and 4 mg
Trial: 9860106
Drug: Flunitrazepam (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (various doses)
Trial: 2198165
Drug: Choline magnesium
RxNorm normalized name: Choline Magnesium Trisalicylate
DrugBank: Choline (DB00122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Choline magnesium trisalicylate (CMT) at increasing doses (50-1,500 mg)
Trial: 2198165
Drug: Choline magnesium
RxNorm normalized name: Choline Magnesium Trisalicylate
DrugBank: Choline (DB00122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Choline magnesium trisalicylate (CMT) at daily 3,000 mg doses for 1 week
Trial: 320654
Drug: Ampicillin pediatric
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ampicillin pediatric suspension (100 mg ampicillin/kg/24 hours divided in 4 doses)
Trial: 320654
Drug: Pivampicillin base
RxNorm normalized name: pivampicillin
DrugBank: Pivampicillin (DB01604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivampicillin base pediatric suspension (64.8 mg/kg/24 hours divided in 4 doses)
Trial: 23489888
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (aspirin 75‐160 mg daily and clopidogrel 300 mg day 1 then 75 mg daily)
Trial: 23489888
Drug: Monotherapy (aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (aspirin 75‐160 mg daily)
Trial: 22829901
Drug: Digested PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digested PR preparations
Trial: 17612824
Drug: Individual Brief
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual Brief Therapeutic Phone Contacts (IBTPC) integrating motivational interviewing and cognitive behavioral therapies
Trial: 15197430
Drug: Polymyxin B-immobilized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymyxin B-immobilized fiber (PMX-F) treatment (n=15)
Trial: 15197430
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (n=10)
Trial: 12076241
Drug: Hormone/estrogen replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone/estrogen replacement therapy (H/ERT)
Trial: 9874467
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa administration for patients receiving cisplatin chemotherapy
Trial: 9874467
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa administration for patients receiving noncisplatin chemotherapy
Trial: 7622259
Drug: 5-day antibacterial
RxNorm normalized name: chloroxylenol 5 MG/ML [QSR Antibacterial]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day antibacterial therapy (Penicillin 300 mg/kg for meningococcal and pneumococcal meningitis; Ampicillin 300 mg/kg for Haemophilus influenzae b meningitis)
Trial: 7622259
Drug: 5-day antibacterial
RxNorm normalized name: chloroxylenol 5 MG/ML [QSR Antibacterial]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day antibacterial therapy
Trial: 7622259
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (8 to 15 days of antibacterial therapy)
Trial: 31357534
Drug: Functional VOO
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional VOO enriched with olive oil PCs (500 mg/kg)
Trial: 31357534
Drug: Functional VOO
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional VOO enriched with olive oil (250 mg/kg) and thyme PCs (250 mg/kg; FVOOT)
Trial: 31357534
Drug: Natural VOO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural VOO (control intervention; olive oil PCs: 80 mg/kg)
Trial: 26110375
Drug: Naloxone sustained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone sustained release (NSR) 2.5 mg
Trial: 26110375
Drug: Naloxone sustained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone sustained release (NSR) 5 mg
Trial: 26110375
Drug: Naloxone sustained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone sustained release (NSR) 10 mg
Trial: 26110375
Drug: Naloxone sustained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone sustained release (NSR) 20 mg
Trial: 19671333
Drug: Trimetazidine (TMZ)
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (TMZ) therapy, n = 70
Trial: 9392401
Drug: Amoxicillin clavulanate
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin clavulanate
Trial: 12194936
Drug: Riboflavin (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riboflavin (1.6 mg/day)
Trial: 2171846
Drug: Guanadrel sulfate
RxNorm normalized name: guanadrel sulfate
DrugBank: Guanadrel (DB00226)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guanadrel sulfate (3 weeks treatment)
Trial: 2171846
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 weeks treatment)
Trial: 619817
Drug: Carmustine and
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carmustine and fluorouracil (two-drug regimen)
Trial: 619817
Drug: Carmustine, fluorouracil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carmustine, fluorouracil, and spironolactone (three-drug regimen)
Trial: 619817
Drug: Three-drug regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug regimen (carmustine, fluorouracil, spironolactone)
Trial: 20949623
Drug: Quadrivalent HPV6/11/16/18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent HPV6/11/16/18 vaccine
Trial: 15206665
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy (15-mg nicotine patch, 4-mg nicotine gum, and/or 10-mg nicotine inhaler)
Trial: 11409480
Drug: Methotrexate (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (25 mg, n=9)
Trial: 8201564
Drug: Collagen shields
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen shields saturated with an antibiotic and a steroid placed in 90 eyes postoperatively
Trial: 8201564
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received the same drugs through a peribulbar/retrobulbar injection in 93 eyes
Trial: 3322763
Drug: Preparation B
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation B (Euthyrox)
Trial: 3322763
Drug: Preparation A
RxNorm normalized name: POVIDONE-IODINE 75 mg in 1 mL TOPICAL SOLUTION [Antiseptic Patient Preoperative Skin Preparation and Surgical Hand Scrub]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation A (L-Thyroxin Henning)
Trial: 3322763
Drug: Preparation C
RxNorm normalized name: other nasal preparation combinations in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation C (Levothyroxine, enos)
Trial: 23949727
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL contrast medium (G30)
Trial: 23949727
Drug: 40 mL
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL contrast medium (G40)
Trial: 23949727
Drug: 50 mL
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mL contrast medium (G50)
Trial: 23949727
Drug: 60 mL
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mL contrast medium (G60)
Trial: 23949727
Drug: 70 mL
RxNorm normalized name: ALCOHOL 70 mL TOPICAL SWAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mL contrast medium (G70)
Trial: 20434204
Drug: Montelukast 5
RxNorm normalized name: montelukast 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 5 mg daily (n = 18)
Trial: 12584827
Drug: Conventional liver
RxNorm normalized name: LIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional liver protecting treatment
Trial: 10512280
Drug: 40 mL
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL epidural saline flush
Trial: 10512280
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL epidural saline flush
Trial: 3510285
Drug: Oral high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral high-dose metoclopramide
Trial: 3510285
Drug: Intravenous high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous high-dose metoclopramide
Trial: 17263269
Drug: 20 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml/kg of intravenous isotonic electrolyte solution (0.9% sodium chloride) (group A)
Trial: 17263269
Drug: 2 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml/kg of intravenous isotonic electrolyte solution (0.9% sodium chloride) (group B)
Trial: 7250779
Drug: Prostaglandin F2‐alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin F2‐alpha gel (2.5 mg, intracervically)
Trial: 7250779
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 tablets (1 mg, orally)
Trial: 30821167
Drug: Montelukast, fexofenadine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast, fexofenadine, and fluticasone nasal spray (Mo-Fex-Flu)
Trial: 30821167
Drug: Cetirizine and
RxNorm normalized name: Cetirizine and pseudoephedrine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine and fluticasone nasal spray (Cet-Flu)
Trial: 28125977
Drug: Clinical decision
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical decision support system (CDSS) for medication review
Trial: 23702393
Drug: Agalsidase alfa
RxNorm normalized name: Agalsidase alfa
DrugBank: Agalsidase alfa (DB15874)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Agalsidase alfa 0.2 mg/kg every 2 weeks
Trial: 23702393
Drug: Agalsidase alfa
RxNorm normalized name: Agalsidase alfa
DrugBank: Agalsidase alfa (DB15874)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Agalsidase alfa 0.1 mg/kg/week
Trial: 23702393
Drug: Agalsidase alfa
RxNorm normalized name: Agalsidase alfa
DrugBank: Agalsidase alfa (DB15874)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Agalsidase alfa 0.2 mg/kg/week
Trial: 21658010
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) glutamine supplementation, 0.283 g glutamine/kg body weight/24 h for the entire ICU stay
Trial: 19701107
Drug: Canfosfamide (400-1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canfosfamide (400-1000 mg/m2 IV) with carboplatin (AUC 6 IV) and paclitaxel (200 mg/m2 IV)
Trial: 18182447
Drug: DHEA 50
RxNorm normalized name: Natrol Mood & Stress DHEA 50mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA 50 mg/d
Trial: 15330905
Drug: Interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2b (3 or 5 million units thrice a week) plus ribavirin (1,000-1,200 mg)
Trial: 15330905
Drug: Interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2b (5 million units) plus ribavirin (1,000-1,200 mg)
Trial: 15330905
Drug: Interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2b (3 million units) plus ribavirin (1,000-1,200 mg)
Trial: 15330905
Drug: Interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2b (higher dose) plus ribavirin (1,000-1,200 mg)
Trial: 9283926
Drug: Fluoxetine (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (in patients with serious physical illness who completed 5 or more weeks)
Trial: 7942576
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg dl alpha‐tocopheryl acetate daily for 30 days
Trial: 30921234
Drug: Ginger consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger consumption (1600-4000mg daily)
Trial: 28504480
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of microneedling and platelet-rich plasma (28 patients, alternative sessions every 2 weeks for a maximum of six sessions)
Trial: 21419002
Drug: Conventional antiparkinsonian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antiparkinsonian drug therapy alone (Control)
Trial: 18211932
Drug: Topical levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical levofloxacin 0.3%
Trial: 18211932
Drug: Topical and
RxNorm normalized name: norgestimate and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical and oral levofloxacin (250 mg)
Trial: 18211932
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin 400 mg
Trial: 18211932
Drug: Oral levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral levofloxacin 250 mg
Trial: 16570297
Drug: Oral methylphenidate
RxNorm normalized name: methylphenidate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methylphenidate (0.8 mg/kg)
Trial: 10731187
Drug: Plant sterol
RxNorm normalized name: plant sterol complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterol or stanol margarines (2 g added to an average daily portion)
Trial: 3937510
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg tablet, twice daily)
Trial: 30624586
Drug: Plasma retinol
RxNorm normalized name: retinol
DrugBank: Vitamin A (DB00162)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plasma retinol (per 10-μg/dL increment)